Aurore Perrot

Aurore Perrot

Institut Claudius Regaud - Toulouse / France
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4604121
-
person_outline Aurore Perrot's MOST POPULAR ARTICLES
1-) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA …P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ...The Lancet 394 (10192), 29-38, 20197952019
2-) Daratumumab plus lenalidomide and dexamethasone for untreated myelomaT Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ...New England Journal of Medicine 380 (22), 2104-2115, 20197932019
3-) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a …M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ...The Lancet 394 (10214), 2096-2107, 20194662019
4-) Oral selinexor–dexamethasone for triple-class refractory multiple myelomaA Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ...New England Journal of Medicine 381 (8), 727-738, 20196532019
5-) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaA Perrot, V Lauwers-Cances, J Corre, N Robillard, C Hulin, ML Chretien, ...Blood, The Journal of the American Society of Hematology 132 (23), 2456-2464, 20184112018